3 research outputs found
'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study.
Invasive aspergillosis in relapsed/refractory acute myeloid leukaemia patients: Results from SEIFEM 2016-B survey
Background: In patients with relapsed/refractory acute myeloid leukaemia (R/R AML) who received salvage chemotherapy, limited and not updated studies explored the incidence of invasive aspergillosis (IA) and the role of antifungal prophylaxis (AP). The aims of this multicentre retrospective ‘SEIFEM 2016-B’ study were as follows: (1) to evaluate the current rate and the outcome of proven/probable IA and (2) to assess the efficacy of AP, in a large ‘real life’ series of patient with R/R AML submitted to salvage chemotherapy. Results: Of 2250 R/R AML patients, a total of 74 cases of IA (5.1%) were recorded as follows: 10 (0.7%) proven and 64 (4.3%) probable. Information about AP were available in 73/74 (99%) patients. Fifty-eight (79%) breakthrough infections occurred, mainly during AP with posaconazole [25 (43%)]. The patients who received AP during salvage chemotherapy showed a benefit from antifungal therapy (AT) than patients who did not received AP [43 (86%) vs 7 (14%); p <.033]. In a multivariate analysis, AP and absence of severe mucositis had a significant favourable effect on overall response rate. Conclusion: Our data demonstrated that the incidence of IA during the salvage chemotherapy is similar to the past. Nevertheless, the attributable mortality rate (AMR) appears to be lower than that previously reported in R/R AML. Further prospective studies should be performed to confirm our preliminary observation and understand and the why a decreased AMR is reported in this setting of high-risk patients
Correction to: Use of low-molecular weight heparin, transfusion and mortality in COVID-19 patients not requiring ventilation (Journal of Thrombosis and Thrombolysis, (2021), 52, 3, (772-778), 10.1007/s11239-021-02429-z)
none63In the original version of the article, the group was mentioned incorrectly. The correct name is "CSS COVID-19 Group". Also, in the Table 4 the p for ICU access and CKD were 0.024 (instead of 0.24) and 0.006 (instead of 0.06). These have been corrected with this erratum.noneGrandone E.; Tiscia G.; Pesavento R.; De Laurenzo A.; Ceccato D.; Sartori M.T.; Mirabella L.; Cinnella G.; Mastroianno M.; Dalfino L.; Colaizzo D.; Vettor R.; Intrieri M.; Ostuni A.; Margaglione M.; Alboini P.E.; Antonioni A.; Aucella F.; Bochicchio G.B.; Carbonelli C.; Carella M.; Castori M.; Centonze A.; Ciliberti G.; Copetti M.; Corritore M.; De Cosmo S.; D'Aloiso L.; D'Errico M.M.; de Matthaeis A.; Del Gaudio A.; Di Giorgio A.; Giambra V.; Greco A.; Florio L.; Fontana A.; Inchingolo V.; Inglese M.; Labonia M.; La Marca A.; Latiano T.; Leone M.; Maiello E.; Mangia A.; Marciano C.; Massa V.; Massafra S.; Orciulo G.; Palladino N.; Perna R.; Piscitelli P.; Piemontese M.; Prencipe M.A.; Raggi P.; Rodriquenz M.G.; Russo R.; Sancarlo D.; Simeone A.; Trischitta V.; Zarrelli M.; Vaira P.; Vergara D.; Vescovi A.Grandone, E.; Tiscia, G.; Pesavento, R.; De Laurenzo, A.; Ceccato, D.; Sartori, M. T.; Mirabella, L.; Cinnella, G.; Mastroianno, M.; Dalfino, L.; Colaizzo, D.; Vettor, R.; Intrieri, M.; Ostuni, A.; Margaglione, M.; Alboini, P. E.; Antonioni, A.; Aucella, F.; Bochicchio, G. B.; Carbonelli, C.; Carella, M.; Castori, M.; Centonze, A.; Ciliberti, G.; Copetti, M.; Corritore, M.; De Cosmo, S.; D'Aloiso, L.; D'Errico, M. M.; de Matthaeis, A.; Del Gaudio, A.; Di Giorgio, A.; Giambra, V.; Greco, A.; Florio, L.; Fontana, A.; Inchingolo, V.; Inglese, M.; Labonia, M.; La Marca, A.; Latiano, T.; Leone, M.; Maiello, E.; Mangia, A.; Marciano, C.; Massa, V.; Massafra, S.; Orciulo, G.; Palladino, N.; Perna, R.; Piscitelli, P.; Piemontese, M.; Prencipe, M. A.; Raggi, P.; Rodriquenz, M. G.; Russo, R.; Sancarlo, D.; Simeone, A.; Trischitta, V.; Zarrelli, M.; Vaira, P.; Vergara, D.; Vescovi, A